Public Company News

There seems to be no end in sight to the run on Blackham Resources’ share price that started in September last year at 15c and touched $1.15 today on the back of more, classic Blackham, super high grade drill hits at the Matilda Gold project – the project that just keeps on giving.  Results out today include 6.0m @ 26.4 g/t gold, including 1.8 metres at a whopping 83.3 g/t, and 15.6 metres at 7.51 g/t.

Blackham Resources shares have surged again with news that the first gold pour at the 100,000+ ounce-a-year Matilda gold project in Wiluna W.A is just weeks away. The first gold bar at Matilda will mark the first major milestone in Blackham’s remarkable revival of the largely mothballed project in Wiluna. Shares in Blackham surged 4.5c to $1.02 on the news. 

Legend Mining have wasted no time getting back into the field for a series of moving loop electromagnetic survey’s at their Rockford project in the Fraser Range, home to the giant Nova-Bollinger nickel deposit. They recently completed a round of exploratory drilling at Rockford which the company says has greatly assisted it to better understand the geology at the Fraser Range.

Cashed up Neometals is returning $11.3 million to shareholders even before production begins at Mt Marion in the December quarter. The savvy junior held $74 million in cash at 30 June and is distributing to shareholders some of the rewards of its great deal making. This is the second time in a year that Neometals have announced a dividend before production has even started. 

Medical cannabis company MGC Pharmaceuticals has agreed to sell two African-based exploration permits and related data for $500,000 in cash. The legacy mining assets no longer form part of the company's core business focus as it finalises the transition away from mineral exploration as Erin Resources and into a leading edge medical marijuana company. 

New drill results suggest that Neometal’s world-class Mt Marion Lithium Project near Coolgardie is set for even further growth in its total resource and that's in addition to the recently announced 160% increase. Neometals, who today announced the conclusion of their 147 hole drilling program at Mt Marion currently hold a 13.8% free carried stake in the project.

ATM business Stargroup looks set to give its balance sheet a boost by again revaluing its stake in South Korean ATM manufacturer NeoICP after the ATM manufacturer and Stargroup supplier posted a bumper result for the 2016 financial year. Stargroup holds an 11.28% strategic stake in private Korean company NeoICP and will shortly receive a $60 000 dividend cheque.

ASX listed biotech company PharmAust today announced that a leading veterinary specialist would conduct more canine trials with its promising anti-cancer drug "MP"L. NSW-based dog cancer specialist, Dr Angela Frimberger, will evaluate MPL either as a monotherapy or in conjunction with chemotherapy in dogs that have not responded to standard cancer treatments.

Financial payments upstart Stargroup, today reported record monthly ATM transactions from its Australia wide ATM machine network for July and predicted its 11thconsecutive quarter of revenue growth. Revenues from the ATM business in July were well in excess of $500,000, more than the company’s entire revenue for FY15 with an annualized rate of $6.7 million.

The highly anticipated drill testing of Hammer Metals' promising Overlander prospect near Mt Isa in Queensland will kick off next month with drill hole positions now determined. Hammer metals, with giant JV partner Newmont, will target a repetition of the famed 220m tonne Ernest Henry iron oxide copper-gold deposit east of Mt Isa. 

Legend Mining today partly realized a profit of $3.46m after selling Independence Gold shares it bought on market back in 2012. The sale provided a healthy kick for the Fraser Range explorer’s share price and a boost to its cash reserves to $8.5 million. In total, Legend has received $5,332,162 worth of cash and script for its $1.87m investment in the then Sirius Resources.

ASX listed cancer drug hopeful Pharmaust have secured additional IP rights to their highly promising anti-cancer drug Monepantel by partially trading off rights to another project under their control. Under the new deal, Pharmaust will receive the remainder of the IP rights to Monepantel that were never transferred to them by the University of NSW.